Astrazeneca and Peregrine Pharma to collaborate on immuno-oncology combination clinical trial
Tuesday, August 25, 2015
Astrazeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial.
Collaboration to evaluate safety and efficacy of Peregrine's investigational phosphatidylserine (ps)-signalling pathway inhibitor, Bavituximab.
Planned phase I/IB trial will evaluate safety and efficacy of bavituximab in combination with durvalumab in multiple solid tumours.
Astrazeneca and Peregrine will collaborate on a non-exclusive basis.
Evaluation of bavituximab in combination with co's investigational anti-PD-l1 immune checkpoint inhibitor, durvalumab.
reuters.com
